Author

R. M. Savic

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 4 Research Focus:drug response / drug discovery· 3 Approach:statistical model· 3 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Assay:clinical cohort / trial· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. A. Bauman· 2 shared C. Dide-Agossou· 2 shared E. Nuermberger· 2 shared G. T. Robertson· 2 shared J. J. N. Goh· 2 shared J. P. Ernest· 2 shared K. Rossmassler· 2 shared M. E. Ramey· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. A. Bauman

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Prospectively predicting BPaMZ Phase IIb outcomes using a translational preclinical mouse to human platform

Q. Wang, J. J. N. Goh, N. Zhang, E. Nuermberger, R. M. Savic

This paper predicts outcomes of BPaMZ tuberculosis treatment regimens using a translational preclinical mouse to human platform, showing potential to shorten treatment duration and prevent relapse.

bioRxiv · Feb 16, 2023 · PreprintPharmacology & Toxicology

Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses

N. D. Walter, J. P. Ernest, C. Dide-Agossou, A. A. Bauman, M. E. Ramey, K. Rossmassler, L. M. Massoudi, S. Pauly, R. Al Mubarak, M. I. Voskuil, F. Kaya, J. P. Sarathy, M. D. Zimmerman, V. Dartois, B. K. Podell, , G. T. Robertson

The paper shows that Mycobacterium tuberculosis in different lung microenvironments have distinct phenotypes and treatment responses in a mouse model.

bioRxiv · Feb 3, 2023 · PreprintMicrobiology

Translational predictions of phase 2a first-in patient efficacy studies for antituberculosis drugs

R. M. Savic, J. J. N. Goh, J. P. Ernest, N. Strydom, Q. Wang, R. C. van Wijk, N. Zhang, A. Deitchman, E. Nuermberger

The paper predicts clinical efficacy of antituberculosis drugs using preclinical PKPD data and translational pharmacology models to reduce phase 2a trial costs and failures.

bioRxiv · Jan 18, 2023Pharmacology & Toxicology

Combination of Mycobacterium tuberculosis RS ratio and CFU improves the ability of murine efficacy experiments to distinguish between drug treatments

C. Dide-Agossou, A. A. Bauman, M. E. Ramey, K. Rossmassler, R. Al Mubarak, S. Pauly, M. I. Voskuil, M. Garcia?Cremades, R. M. Savic, P. Nahid, C. M. Moore, R. Tasneen, E. Nuermburger, G. T. Robertson, N. D. Walter

bioRxiv · Dec 21, 2021Microbiology